Takato Nishino

St. Luke's International Hospital

Papers

4

Total Citations

10

H-Index

2

About

Dr. Takato Nishino is a urologic surgeon and researcher whose work centers on optimizing surgical and oncological outcomes for high-risk prostate cancer, particularly through robot-assisted radical prostatectomy (RARP). His major contributions include rigorous evaluations of extended lymph node dissection (ePLND) and neoadjuvant hormonal therapy, challenging established practices. A 2025 study (4 citations) found that ePLND may not provide a therapeutic benefit for biochemical recurrence in intermediate-to high-risk patients, while a multicenter propensity-matched analysis (3 citations) demonstrated the efficacy of neoadjuvant hormonal therapy for high-risk cases in Japan. Dr. Nishino has also advanced surgical technique, notably by optimizing first trocar access for the da Vinci X/Xi system using optical trocar entry through the upper abdominal quadrant (2 citations). His 2025 comparison of neoadjuvant chemohormonal therapy versus pelvic lymphadenectomy (1 citation) further refines treatment strategies for very-high-risk disease. By combining retrospective multicenter data with technical innovation, Dr. Nishino provides evidence-based guidance for urologists navigating the complex landscape of aggressive prostate cancer management.

Research Focus

Key Achievements

2
H-Index
4
Papers
10
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Extended Lymph Node Dissection May Not Provide a Therapeutic Benefit in Patients with Intermediate-to High-Risk Prostate Cancer Treated with Robotic-Assisted Radical Prostatectomy
4 citations · 2025
📈 Most Prolific Year: 2025 (3 Papers)
🤝 Key Collaborators: 39
🏛 Institutions: St. Luke's International Hospital

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago